KRAS and Patent ductus arteriosus: On analyzing the data on markers predictive of ICPIs therapy response, several factors (higher mean TMB, higher percentage of high and ultrahigh TMB) suggests that, as a group, the KRAS wild-type PDA may be more responsive to ICPIs therapy than the KRAS mutated PDA.